Medication info
Yucita Tablet 100 mg (Sitagliptin Hydrochloride Hydrate)

Yucita Tablet 100 mg (Sitagliptin Hydrochloride Hydrate)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›113.4mg / 1 tablet
Manufacturer / importer
Yuyoung Pharmaceutical Co., Ltd.
Appearance
Bright brown, circular, bilayered film-coated tablet
Packaging
28 tablets/box [14 tablets/PTP x 2]
Approval status
Active

MFDS item code 202101748 · Approved 2021.02.22 · Insurance code 648204620

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
Administer 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medication may be taken regardless of meals. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because the dose must be adjusted according to renal function, assessment of renal function is recommended before and periodically after starting this medication. 1. No dose adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily in patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medication may be administered regardless of the timing of dialysis.

Ingredients

Manufacturer
Yuyoung Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

  • Difficulty in blood glucose control for patients with type 2 diabetes
View approved original text

This medication is used in conjunction with diet and exercise to improve blood glucose control in patients with type 2 diabetes. It can be administered as monotherapy to patients starting treatment, and if blood glucose control is difficult with monotherapy, it may be used in combination with metformin. Additionally, it can be further combined with sulfonylureas, metformin, thiazolidinediones, or insulin in patients who do not achieve adequate blood glucose control with these treatments. This variety of treatment options effectively improves blood glucose control.

How to take

Adult dose

Administer 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medication may be taken regardless of meals. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because the dose must be adjusted according to renal function, assessment of renal function is recommended before and periodically after starting this medication. 1. No dose adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily in patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medication may be administered regardless of the timing of dialysis.

Precautions

This medication may cause allergic reactions; if symptoms such as skin rash or difficulty breathing occur, discontinue use immediately and consult a physician. Acute pancreatitis, a serious inflammatory condition of the pancreas, may develop, thus immediate medical attention is required if symptoms such as abdominal pain, nausea, or vomiting arise. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis. Avoid taking this medication if you have allergies to this drug or its components. Patients with impaired renal function should have their dosage adjusted and take the medication under a physician's guidance. Hypoglycemic symptoms may occur while using this medication, especially when taken with insulin or sulfonylureas, thus close monitoring of blood glucose levels is advised. If severe joint pain or skin blisters occur, consult a physician immediately and stop taking the medication. Pregnant or breastfeeding women are advised not to use this medication, and safety and effectiveness have not been established for children or adolescents under 18 years of age. Elderly patients may experience decreased renal function, necessitating dosage adjustments and regular renal function tests. In case of overdose, visit a hospital immediately for appropriate treatment, as this medication may be partially removed via hemodialysis. This medication generally does not interact significantly with other medications, but caution is necessary when taken with specific drugs, so consult healthcare providers. Report any unusual symptoms during use to healthcare providers and take appropriate measures.

Side effects

Anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, hypoglycemia, nasopharyngitis, upper respiratory infection, headache, diarrhea, abdominal pain, nausea, peripheral edema, constipation, vomiting, arthralgia with severe and disabling symptoms, blistering dermatitis, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, elevated liver enzymes, acute renal failure, rash, urticaria, cutaneous vasculitis, pneumonia, diabetes complications, metabolic acidosis, falls, cardiac arrest, dyspepsia, dizziness, increased ALT, increased AST, increased serum triglycerides, gastritis, increased low-density lipoprotein, hyperglycemia, weight loss, hypertension, hypernatremia, erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container that is protected from air, at a temperature between 1 and 30 degrees Celsius. Proper storage will maintain the drug's effectiveness and prevent degradation.

Appearance and packaging

Appearance

Bright brown, circular, bilayered film-coated tablet

Package unit

28 tablets/box [14 tablets/PTP x 2]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.